Biomarkers in clear cell renal cell carcinoma

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57, 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• George DJ, Kaelin WG Jr. The von Hippel–Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med.349, 419–421 (2003).
   PubMed Web of Science ®Google Scholar
• Linehan WM, Pinto PA, Srinivasan R et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res..13, S671–S679 (2007).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92, 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Figlin R. Prognostic factors and biomarkers for renal cell carcinoma “surrogate markers”. Presented at: 4th International Congress on Kidney and Bladder Cancer. Orlando, FL, USA, 27–31 March 2007.
   Google Scholar
• Ebos JM, Bocci G, Man S et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol. Cancer Res.2, 315–326 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17, 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan–Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol.23, 832–841 (2005).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer110, 543–550 (2007).
   PubMed Web of Science ®Google Scholar
• Beck SD, Patel MI, Snyder ME et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann. Surg. Oncol.11, 71–77 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol.20, 2376–2381 (2002).
   PubMed Web of Science ®Google Scholar
• Presti JC Jr, Wilhelm M, Reuter V et al. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J. Urol.167, 1464–1468 (2002).
   Google Scholar
• Bukowski RM. Future directions in targeted therapy for renal carcinoma. Extended education session; biology and targeted therapy for advanced renal cell carcinoma. Presented at: American Society of Clinical Oncology, 2007 ASCO Annual Meeting. Chicago, IL, USA, June 1–5 2007.
   Google Scholar
• Deprimo SE, Bello CL, Smeraglia J et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med.5, 32 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Menetrier-Caux C et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 – from the Groupe Francais d'Immunotherapie. J. Clin. Oncol.22, 2371–2378 (2004).
   PubMed Web of Science ®Google Scholar
• Negrier S, Chabaud S, Escudier B et al. Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). J. Clin. Oncol.25, S18 (2007) (Abstract 5044).
   Google Scholar
• Teratani T, Domoto T, Kuriki K et al. Detection of transcript for brain-type fatty acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology69, 236–240 (2007).
   PubMed Web of Science ®Google Scholar
• Battagli C, Uzzo RG, Dulaimi E et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res.63, 8695–8699 (2003).
   PubMed Web of Science ®Google Scholar
• Tickoo SK, Alden D, Olgac S et al. Immunohistochemical expression of hypoxia inducible factor-1α and its downstream molecules in sarcomatoid renal cell carcinoma. J. Urol.177, 1258–1263 (2007).
   PubMedGoogle Scholar
• Lidgren A, Hedberg Y, Grankvist K et al. The expression of hypoxia-inducible factor-1α is a favorable independent prognostic factor in renal cell carcinoma. Clin. Cancer Res.11, 1129–1135 (2005).
   PubMed Web of Science ®Google Scholar
• Sharifi N, Farrar WL. Perturbations in hypoxia detection: a shared link between hereditary and sporadic tumor formation? Med. Hypotheses66, 732–735 (2006).
   Google Scholar
• Lam JS, Pantuck AJ, Belldegrun AS et al. G250: a carbonic anhydrase IX monoclonal antibody. Curr. Oncol. Rep.7, 109–115 (2005).
   PubMedGoogle Scholar
• Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J. Urol.171, 2461–2466 (2004).
   PubMed Web of Science ®Google Scholar
• Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res..11, 3714–3721 (2005).
   PubMed Web of Science ®Google Scholar
• Upton MP, Parker RA, Youmans A et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. (1997)28, 488–495 (2005).
   PubMed Web of Science ®Google Scholar
• Li G, Feng G, Gentil-Perret A et al. CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy. Clin. Exp. Metastasis24, 149–155 (2007).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Vaziri S, Rini BI et al. Use of Von-Hippel–Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). J. Clin. Oncol.25, S18 (2007) (Abstract 5012).
   Google Scholar
• Yao M, Yoshida M, Kishida T et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst.94, 1569–1575 (2002).
   PubMed Web of Science ®Google Scholar
• Nagao K, Yamaguchi S, Matsuyama H et al. Allelic loss of 3p25 associated with alterations of 5q22.3 approximately q23.2 may affect the prognosis of conventional renal cell carcinoma. Cancer Genet. Cytogenet.160, 43–48 (2005).
   Google Scholar
• Blumke K, Bilkenroth U, Schmidt U et al. Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. Oncol. Rep.14, 895–899 (2005).
   PubMedGoogle Scholar
• Weiss RH, Borowsky AD, Seligson D et al. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J. Urol.177, 63–68; discussion 68–69 (2007).
   PubMed Web of Science ®Google Scholar
• Krambeck AE, Dong H, Thompson RH et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Res.13, 1749–1756 (2007).
   PubMed Web of Science ®Google Scholar
• Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer72, 424–430 (1997).
   PubMed Web of Science ®Google Scholar
• Wan X, Shen N, Mendoza A et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1α/VEGF signaling. Neoplasia8, 394–401 (2006).
   PubMed Web of Science ®Google Scholar